Research ArticleArticle
CB1 Receptor Allosteric Modulators Display Both Agonist and Signaling Pathway Specificity
Gemma L. Baillie, James G. Horswill, Sharon Anavi-Goffer, Patricia H. Reggio, Daniele Bolognini, Mary E. Abood, Sean McAllister, Phillip G. Strange, Gary J. Stephens, Roger G. Pertwee and Ruth A. Ross
Molecular Pharmacology February 2013, 83 (2) 322-338; DOI: https://doi.org/10.1124/mol.112.080879
Gemma L. Baillie
School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom (G.L.B., S.A.G., D.B., R.G.P., R.A.R.); Prosidion Limited, Oxford, United Kingdom (J.H.). School of Pharmacy, University of Reading, Reading, United Kingdom (P.G.S., G.J.S.); University of North Carolina, Greensboro, North Carolina (P.H.R.); Temple University, Philadelphia, Pennsylvania (M.E.A.); Department of Behavioral Sciences and Molecular Biology, Ariel University Center, Israel (S.A.G.); California Pacific Medical Center, Research Institute, San Francisco, California (S.McA.); Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (R.A.R.).
James G. Horswill
School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom (G.L.B., S.A.G., D.B., R.G.P., R.A.R.); Prosidion Limited, Oxford, United Kingdom (J.H.). School of Pharmacy, University of Reading, Reading, United Kingdom (P.G.S., G.J.S.); University of North Carolina, Greensboro, North Carolina (P.H.R.); Temple University, Philadelphia, Pennsylvania (M.E.A.); Department of Behavioral Sciences and Molecular Biology, Ariel University Center, Israel (S.A.G.); California Pacific Medical Center, Research Institute, San Francisco, California (S.McA.); Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (R.A.R.).
Sharon Anavi-Goffer
School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom (G.L.B., S.A.G., D.B., R.G.P., R.A.R.); Prosidion Limited, Oxford, United Kingdom (J.H.). School of Pharmacy, University of Reading, Reading, United Kingdom (P.G.S., G.J.S.); University of North Carolina, Greensboro, North Carolina (P.H.R.); Temple University, Philadelphia, Pennsylvania (M.E.A.); Department of Behavioral Sciences and Molecular Biology, Ariel University Center, Israel (S.A.G.); California Pacific Medical Center, Research Institute, San Francisco, California (S.McA.); Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (R.A.R.).
Patricia H. Reggio
School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom (G.L.B., S.A.G., D.B., R.G.P., R.A.R.); Prosidion Limited, Oxford, United Kingdom (J.H.). School of Pharmacy, University of Reading, Reading, United Kingdom (P.G.S., G.J.S.); University of North Carolina, Greensboro, North Carolina (P.H.R.); Temple University, Philadelphia, Pennsylvania (M.E.A.); Department of Behavioral Sciences and Molecular Biology, Ariel University Center, Israel (S.A.G.); California Pacific Medical Center, Research Institute, San Francisco, California (S.McA.); Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (R.A.R.).
Daniele Bolognini
School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom (G.L.B., S.A.G., D.B., R.G.P., R.A.R.); Prosidion Limited, Oxford, United Kingdom (J.H.). School of Pharmacy, University of Reading, Reading, United Kingdom (P.G.S., G.J.S.); University of North Carolina, Greensboro, North Carolina (P.H.R.); Temple University, Philadelphia, Pennsylvania (M.E.A.); Department of Behavioral Sciences and Molecular Biology, Ariel University Center, Israel (S.A.G.); California Pacific Medical Center, Research Institute, San Francisco, California (S.McA.); Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (R.A.R.).
Mary E. Abood
School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom (G.L.B., S.A.G., D.B., R.G.P., R.A.R.); Prosidion Limited, Oxford, United Kingdom (J.H.). School of Pharmacy, University of Reading, Reading, United Kingdom (P.G.S., G.J.S.); University of North Carolina, Greensboro, North Carolina (P.H.R.); Temple University, Philadelphia, Pennsylvania (M.E.A.); Department of Behavioral Sciences and Molecular Biology, Ariel University Center, Israel (S.A.G.); California Pacific Medical Center, Research Institute, San Francisco, California (S.McA.); Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (R.A.R.).
Sean McAllister
School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom (G.L.B., S.A.G., D.B., R.G.P., R.A.R.); Prosidion Limited, Oxford, United Kingdom (J.H.). School of Pharmacy, University of Reading, Reading, United Kingdom (P.G.S., G.J.S.); University of North Carolina, Greensboro, North Carolina (P.H.R.); Temple University, Philadelphia, Pennsylvania (M.E.A.); Department of Behavioral Sciences and Molecular Biology, Ariel University Center, Israel (S.A.G.); California Pacific Medical Center, Research Institute, San Francisco, California (S.McA.); Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (R.A.R.).
Phillip G. Strange
School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom (G.L.B., S.A.G., D.B., R.G.P., R.A.R.); Prosidion Limited, Oxford, United Kingdom (J.H.). School of Pharmacy, University of Reading, Reading, United Kingdom (P.G.S., G.J.S.); University of North Carolina, Greensboro, North Carolina (P.H.R.); Temple University, Philadelphia, Pennsylvania (M.E.A.); Department of Behavioral Sciences and Molecular Biology, Ariel University Center, Israel (S.A.G.); California Pacific Medical Center, Research Institute, San Francisco, California (S.McA.); Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (R.A.R.).
Gary J. Stephens
School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom (G.L.B., S.A.G., D.B., R.G.P., R.A.R.); Prosidion Limited, Oxford, United Kingdom (J.H.). School of Pharmacy, University of Reading, Reading, United Kingdom (P.G.S., G.J.S.); University of North Carolina, Greensboro, North Carolina (P.H.R.); Temple University, Philadelphia, Pennsylvania (M.E.A.); Department of Behavioral Sciences and Molecular Biology, Ariel University Center, Israel (S.A.G.); California Pacific Medical Center, Research Institute, San Francisco, California (S.McA.); Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (R.A.R.).
Roger G. Pertwee
School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom (G.L.B., S.A.G., D.B., R.G.P., R.A.R.); Prosidion Limited, Oxford, United Kingdom (J.H.). School of Pharmacy, University of Reading, Reading, United Kingdom (P.G.S., G.J.S.); University of North Carolina, Greensboro, North Carolina (P.H.R.); Temple University, Philadelphia, Pennsylvania (M.E.A.); Department of Behavioral Sciences and Molecular Biology, Ariel University Center, Israel (S.A.G.); California Pacific Medical Center, Research Institute, San Francisco, California (S.McA.); Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (R.A.R.).
Ruth A. Ross
School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom (G.L.B., S.A.G., D.B., R.G.P., R.A.R.); Prosidion Limited, Oxford, United Kingdom (J.H.). School of Pharmacy, University of Reading, Reading, United Kingdom (P.G.S., G.J.S.); University of North Carolina, Greensboro, North Carolina (P.H.R.); Temple University, Philadelphia, Pennsylvania (M.E.A.); Department of Behavioral Sciences and Molecular Biology, Ariel University Center, Israel (S.A.G.); California Pacific Medical Center, Research Institute, San Francisco, California (S.McA.); Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada (R.A.R.).
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
Cannabinoid CB1 Allosteric Modulators: Signaling Specificity
Gemma L. Baillie, James G. Horswill, Sharon Anavi-Goffer, Patricia H. Reggio, Daniele Bolognini, Mary E. Abood, Sean McAllister, Phillip G. Strange, Gary J. Stephens, Roger G. Pertwee and Ruth A. Ross
Molecular Pharmacology February 1, 2013, 83 (2) 322-338; DOI: https://doi.org/10.1124/mol.112.080879
Research ArticleArticle
Cannabinoid CB1 Allosteric Modulators: Signaling Specificity
Gemma L. Baillie, James G. Horswill, Sharon Anavi-Goffer, Patricia H. Reggio, Daniele Bolognini, Mary E. Abood, Sean McAllister, Phillip G. Strange, Gary J. Stephens, Roger G. Pertwee and Ruth A. Ross
Molecular Pharmacology February 1, 2013, 83 (2) 322-338; DOI: https://doi.org/10.1124/mol.112.080879
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement